Sensus Healthcare Study Shows SRT-100® Prevents Keloid Recurrence at Taiwan’s Tri-Service Military Hospital
Sensus Healthcare, Inc. (Nasdaq: SRTS), a leading medical device company focused on providing effective, non-invasive, and cost-efficient treatments for both oncological and non-oncological skin conditions, has announced the publication of a study titled “Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)” in the Annals of Plastic Surgery.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive medical device treatments for oncological and non-oncological skin conditions, has announced the publication of a study titled “Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)” in the Annals of Plastic Surgery. This retrospective, single-site study evaluated the clinical outcomes of combining surgical excision of keloids with primary wound closure followed by adjuvant Superficial Radiation Therapy (SRT) using Sensus Healthcare’s SRT-100® system.
The study, conducted at Tri Service Military Hospital in Taiwan, where the SRT-100® system has been in use since 2023, involved 12 patients with 16 keloids. The study’s follow-up visits revealed that there was no recurrence of keloids in the majority of the patients, with most of them being followed for more than six months. This significant outcome highlights the potential of the SRT-100® system in preventing keloid recurrence, further validating its effectiveness as part of a comprehensive treatment approach. This publication represents Sensus Healthcare’s first study conducted in Asia, expanding its footprint in global research and clinical outcomes.
“We are delighted to see the SRT-100® system featured in this prestigious peer-reviewed publication, further validating its role in keloid management,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “Keloids can be both physically and emotionally distressing for patients, and traditional treatment approaches often lead to high recurrence rates with even larger keloids. By integrating SRT following surgical excision, we provide a non-invasive, targeted solution that significantly reduces recurrence and improves patient outcomes. This study reinforces our commitment to advancing clinically proven therapies that enhance quality of life for those suffering from dermatological issues, including keloids, which are relatively more prevalent in Southeast Asian populations.”
Keloids are benign, fibrous growths of tissue that form after an injury, typically characterized by the abnormal overgrowth of scar tissue beyond the original wound site. These growths often cause discomfort, itching, and pain, as well as emotional distress due to their cosmetic appearance. Traditional treatment options, including corticosteroid injections, cryotherapy, and laser therapy, frequently yield inconsistent results and are known for their high recurrence rates. This creates a significant challenge in the management of keloids, particularly for patients who have experienced multiple unsuccessful treatments in the past.
The results of this study suggest that combining Superficial Radiation Therapy (SRT) with surgical excision of keloids can significantly improve treatment outcomes by reducing the chances of keloid regrowth. SRT targets the underlying fibroblast activity that leads to keloid formation, without the need for invasive procedures or long recovery periods. The study’s findings show that this combined approach provides a more reliable and effective long-term solution for keloid patients.
The SRT-100® system is a non-invasive treatment device that uses low-dose superficial radiation to address various skin conditions, including keloids. By delivering targeted radiation, the system helps to reduce fibroblast activity, preventing the recurrence of keloids after excision. This approach provides patients with a safe, effective treatment alternative to the more invasive and often inconsistent methods traditionally used to treat keloids.
The clinical success of this study demonstrates how the integration of SRT with surgical excision can dramatically enhance the management of keloids, reducing recurrence rates and providing a new treatment option for patients who may have previously faced limited alternatives. The results of this study are particularly meaningful given the relatively high prevalence of keloids in Southeast Asia, where patients often experience more severe keloid scarring.
The study is now available online in the March 2025 issue of the Annals of Plastic Surgery, contributing valuable clinical evidence to the growing body of research supporting the use of the SRT-100® system in dermatological treatments. This publication serves as a testament to the growing acceptance of superficial radiation therapy as a reliable method for addressing keloid recurrence.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global leader in developing non-invasive, cutting-edge technologies for treating skin cancer and keloids. The company’s portfolio includes its flagship SRT-100® system, which utilizes superficial radiotherapy (SRT) technology to offer patients a safer, more effective alternative to traditional surgical treatments. With its focus on precision, adaptability, and patient-centered care, Sensus Healthcare aims to advance dermatological treatments and improve outcomes for patients worldwide. Through continued innovation and clinical validation, Sensus Healthcare is committed to providing healthcare professionals with the tools necessary to address complex dermatological conditions with efficiency and accuracy.
